3SBio Reports Phase II NSCLC Data for Tivunatamig Plus Chemotherapy

In first-line advanced NSCLC, median PFS was 13.6 months in squamous and 13.8 months in non-squamous disease. ORR was 80.7% and 77.5%, respectively, versus controls; safety was broadly comparable to control.